** U.S.-listed shares of Israel based drug developer PainReform PRFX.O fall 18.4% to $4 premarket
** Co says its lead experimental pain relief treatment, PRF-110, did not meet the main goal of a late-stage study
** Co announced interim data from the late-stage study in November where it was testing PRF-110 to study the effect of the treatment in reducing pain over 72 hours
** Co had previously said that data from the late-stage pertaining to the last 24-hour period of the 72-hour study was unclear
** After further investigation co says the data could not be clarified to satisfy the study's main goal
** Co says despite setback, it has started R&D activities to better understand the effects of the treatment "to potentially resolve this issue to support future clinical trials"
** PRF-110 was tested to provide prolonged pain relief while reducing the need for opioids, in the post-surgical setting
** Up to last close, stock down 92.6% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。